
Genetic analysis finds 125 loci shared by insomnia and CRP, with Mendelian randomization favoring an effect from insomnia liability to inflammation.
Treatment with trastuzumab (Herceptin) boosts risk of heart failure or cardiomyopathy in breast cancer survivors, an observational study affirmed.
Women who received trastuzumab alone were 4.12 times more likely (95% CI 2.30 to 7.42) to go into heart failure after accounting for other factors, Erin Aiello Bowles, MPH, of the Group Health Research Institute in Seattle, and colleagues found.
Read the full story:
Source: MedPage Today





